Acromegaly is an uncommon adult hormonal condition brought on by an overabundance of growth hormone, typically from a benign pituitary tumor. In addition to thicker skin and a deeper voice, it causes abnormal enlargement of the hands, feet, jaw, and facial features. Headaches and joint discomfort are among the symptoms, which appear gradually. Acromegaly can lead to issues such as heart disease, hypertension, and type 2 diabetes if left untreated. Radiation, medicine, and surgery are available forms of treatment. The acromegaly pipeline analysis by Expert Market Research focuses on various treatment options for this disease.
Major companies involved in acromegaly pipeline analysis include Crinetics Pharmaceuticals Inc., Immunwork, Inc. and Camurus AB, among others.
Leading drugs currently in the pipeline include Paltusotine, CAM2029, and others.
Advancements in novel therapies are driving pipeline growth. Increased investment in research and development, along with regulatory support, is accelerating clinical trials and new treatment approvals.
The Acromegaly Pipeline Analysis Report by Expert Market Research gives comprehensive insights into acromegaly therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for acromegaly. The acromegaly report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The acromegaly pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with acromegaly treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to acromegaly.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The pathogenesis of acromegaly is based on the overproduction of growth hormone (GH), typically from a pituitary adenoma, which raises the levels of insulin-like growth factor 1 (IGF-1). The liver produces more IGF-1 when GH is oversecreted, which leads to aberrant organ, soft tissue, and bone growth. The hallmarks and comorbidities of acromegaly are caused by the disruption of normal metabolic and cellular pathways caused by persistently elevated GH and IGF-1.
Surgery to remove the pituitary tumor, usually in a transsphenoidal fashion, with the goal of achieving biochemical remission, is the main treatment for acromegaly. Medical therapy with somatostatin analogs, GH receptor antagonists, or dopamine agonists is used to regulate hormone levels if surgery is not successful or is not feasible. When medication and surgery are not enough to treat a persistent or recurrent condition, radiation therapy may be explored. Treatment is tailored to the patient's health, hormone levels, and tumor size.
The prevalence of acromegaly, ranges from 2.8 to 13.7 instances per 100,000 people worldwide, with pooled estimates of 5.9 occurrences per 100,000. About 0.38 cases per 100,000 person-years is the annual incidence. It usually takes until middle age to be diagnosed because of its gradual progression. In recent years, the stated prevalence has increased due to improved diagnostic techniques.
This section of the report covers the analysis of acromegaly drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, a wide range of development stages and advancements toward possible treatments can be observed in acromegaly pipeline, where the bulk of candidates—60%—are in Phase III, with 20% in both Phase II and Phase I.
The drug molecule categories covered under acromegaly pipeline analysis include monoclonal antibodies, peptides, polymers, small molecules and gene therapies. The acromegaly report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for the condition.
Small molecules are emerging as promising agents in the Acromegaly pipeline. For example, Paltusotine, is the first oral, once-daily, selectively targeted nonpeptide agonist for the somatostatin receptor type 2 (SST2).
The EMR report for acromegaly pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in acromegaly clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for acromegaly. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of acromegaly drug candidates.
Paltusotine, developed by Crinetics Pharmaceuticals, is an investigational oral, once-daily selective somatostatin receptor type 2 (SST2) agonist designed to treat acromegaly. In the Phase 3 PATHFNDR-2 trial, 56% of untreated patients achieved normalized IGF-1 levels, compared to 5% with placebo. The drug was well tolerated, with no serious adverse events reported. For adults with acromegaly, paltusotine will be the first and only oral, once-daily, selective somatostatin receptor type 2 nonpeptide agonist.
The safety and effectiveness of Camurus AB's once-monthly octreotide subcutaneous (SC) depot were assessed in the 52-week Phase 3 open-label ACROINNOVA 2 research, which produced positive, final topline results (CAM2029). The study comprised 135 acromegaly patients who were biochemically controlled (IGF-1≤1xULN) or uncontrolled at screening on stable doses of standard-of-care (SoC) with first-generation somatostatin ligands (SRL); 81 of these patients were new to the study, and 54 were rollover patients from a 24-week randomized treatment with either a placebo or octreotide SC depot (ACROINNOVA 1).
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share